BUD vs MDLZ
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
The Advanced Deterministic Scorecard reveals a weak financial health profile with a Piotroski F-Score of just 2/9, indicating significant operational and profitability concerns. Despite this, the stock trades above its Graham Number of $52.90 at $69.88, supported by a bullish analyst recommendation and strong recent price performance. Earnings growth has collapsed year-over-year (-48.6%), yet the company consistently beats estimates, showing some earnings quality. Profit margins and cash flow generation remain solid, but missing key financial health metrics like ROE, ROA, and Altman Z-Score limits confidence in stability. The dividend is sustainable with a 37.5% payout ratio, but insider sentiment and technical trend are weak.
MDLZ presents a conflicted profile with a stable Piotroski F-Score of 4/9 but severe valuation gaps, trading at $57.42 against a Graham Number of $29.28 and an Intrinsic Value of $13.23. While revenue growth remains robust at 9.3%, the company is facing a critical earnings collapse (-60.4% YoY) and an unsustainable dividend payout ratio of 102.65%. The strong analyst 'buy' consensus and consistent earnings beat history are offset by poor liquidity ratios and a bearish technical trend.
Compare Another Pair
Related Comparisons
BUD vs MDLZ: Head-to-Head Comparison
This page compares Anheuser-Busch InBev SA/NV (BUD) and Mondelez International, Inc. (MDLZ) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.